Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320045 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects
A Phase 1 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02320045 is a Phase 1 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 38 participants.
The verdict
NCT02320045, a Phase 1 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function
Interventions
- DRUG ITCA 650 (Exenatide in osmotic mini pump)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320045
The ClinicalTrials.gov registry entry for NCT02320045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ITCA 650 (Exenatide in osmotic mini pump) is the first listed.
NCT02320045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320045 about?
NCT02320045 is a clinical study titled "Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects". A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function
What is the current status of trial NCT02320045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-11. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02320045?
The interventions under investigation include: ITCA 650 (Exenatide in osmotic mini pump) (DRUG).
Who is sponsoring clinical trial NCT02320045?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.